🔎 Trials Near Me

Beranda › Amiloidosis › Maryland

Uji klinis Amiloidosis di Maryland

7 studi untuk Amiloidosis mencari peserta di lokasi di Maryland.

Kota di Maryland

Teks studi resmi (Bahasa Inggris)

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

  • Research Site, Baltimore
Menerima pesertaStudi observasional
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06465810

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  • Clinical Trial Site, Baltimore
Menerima pesertaFase 3
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07052903

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

  • Clinical Trial Site, Baltimore
Menerima pesertaFase 3
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07223203

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

  • Clinical Trial Site, Baltimore
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT04561518

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  • University of Maryland Medical Center, Baltimore
  • Johns Hopkins University, Baltimore
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT06563895

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

  • National Institutes of Health Clinical Center, Bethesda
Menerima pesertaFase 1
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT06974877

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

  • Johns Hopkins University, Baltimore
Menerima pesertaFase 3
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 27 Mar 2026 · NCT06128629

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.